Drug Trial Radar · NCT01194258
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Aug 2010
Primary completion
Aug 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to compare Humalog (insulin lispro)-recombinant human hyaluronidase PH20 (rHuPH20) or Novolog (insulin aspart)-rHuPH20 to insulin lispro for the treatment of Type 2 diabetes mellitus (T2DM) in basal-bolus therapy.
Conditions
- Diabetes Mellitus, Type II
Interventions
Insulin lisproDrug
Insulin aspartDrug
Recombinant human hyaluronidase PH20Drug
Insulin glulisineDrug
Insulin glargineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C) at the End of Each Treatment PeriodTime frame: Baseline, Week 12 and Week 24
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
John Muir Physician Network Clinical Research Center
Concord, California
Medical Group of Encino
Encino, California
AMCR Institute, Inc.
Escondido, California
Marin Endocrine Care and Research
Greenbrae, California
Mills-Peninsula Health Services
San Mateo, California
Center for Diabetes and Endocrine Care
Hollywood, Florida
Diabetes Research Institute
Miami, Florida
Baptist Diabetes Associates
Miami, Florida
Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho
Mid-America Diabetes Associates
Wichita, Kansas
Tulane University Health Sciences Center
New Orleans, Louisiana
Medstar Research Institute
Hyattsville, Maryland
Henry Ford Health System
Detroit, Michigan
International Diabetes Center
Minneapolis, Minnesota
Mercury Street Medical
Butte, Montana
Desert Endocrinology
Henderson, Nevada
Diabetes and Endocrinology Associates, PC
Rudd, North Carolina
UT Southwestern Medical Center at Dallas
Dallas, Texas
Texas Diabetes and Endocrinology
Round Rock, Texas
Cetero Research-San Antonio
San Antonio, Texas
West Olympia Internal Medicine
Olympia, Washington
University of Washington School of Medicine
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.